Bhuvana Setty

Dr. Bhuvana Setty


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AJAmanda E. Jacobson
Amanda E. Jacobson
NSNilay Shah
Nilay Shah
BSBhuvana Setty
Bhuvana Setty

19 May 2010 in Current Hematologic Malignancy Reports
Verified
Journal Article
Closed access
PDF file
BSBhuvana Setty
Bhuvana Setty
ATAmanda M. Termuhlen
Amanda M. Termuhlen

1 May 2019 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
PPPriyal Patel
Priyal Patel
RRRyan Roberts
Ryan Roberts
JCJason Cole
Jason Cole
MSMelissa Stalling
Melissa Stalling
KNKathleen Nicol
Kathleen Nicol
BSBhuvana Setty
Bhuvana Setty
Myoepithelial carcinomas (MC) represent aggressive tumors that occur in a myriad of ages and anatomic locations. The rarity and histologic similarity with other tumors make them difficult to diagnosis. We report an extremely rare case of a right ventricular outflow tract mass identified to be an intracardiac MC in a 4-month-old male infant. Pathology revealed an EWS-KLF15 translocation. Treatment included gross total resection and intensive chemotherapy. Recurrent cardiac mass with brain metastasis was seen 16 months after primary diagnosis. We describe the rarity of intracardiac MC in pediatric patients and the challenges encountered in the multimodal management of this patient.

25 May 2011 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BSBhuvana Setty
Bhuvana Setty
NYNicholas D. Yeager
Nicholas D. Yeager
RBRajinder P. Bajwa
Rajinder P. Bajwa

25 July 2022 in The Cancer Journal
Verified
Journal Article
Open access
MPMarcelo de Souza Fernandes Pereira
Marcelo de Souza Fernandes Pereira
DCDavid R. Carr
David R. Carr
MGMargaret E. Gatti-Mays
Margaret E. Gatti-Mays
MOMallery R. Olsen
Mallery R. Olsen
BSBhuvana Setty
Bhuvana Setty
DLDean Lee
Dean Lee
Natural killer (NK) cells possess an innate ability to recognize cancer and are key mediators of cytotoxic efficacy for anticancer antibodies. Recent advances in the ability to generate, qualify, and safely infuse NK cells have led to a wide variety of clinical trials in oncology. Although their efficacy is best established for liquid cancers, their potential application in solid cancers has received increased attention. Here, we provide general background across a disparate group of exemplary solid tumors for which there is evidence for an NK cell role, discuss NK cell recognition motifs specific to each and murine and human studies of each that are supportive of NK cell adoptive immunotherapy, and end with special considerations relevant to the solid tumor microenvironment.

30 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RURituraj Upadhyay
Rituraj Upadhyay
BKBrett Klamer
Brett Klamer
JMJennifer K Matsui
Jennifer K Matsui
VCVikram B. Chakravarthy
Vikram B. Chakravarthy
TSThomas Scharschmidt
Thomas Scharschmidt
SBSujith Baliga
Sujith Baliga
Background: Pediatric patients with metastatic and/or recurrent solid tumors have poor survival outcomes despite standard-of-care systemic therapy. Stereotactic ablative radiation therapy (SABR) may improve tumor control. We report the outcomes with the use of SABR in our pediatric solid tumor population. Methods: This was a single-institutional study in patients < 30 years treated with SABR. The primary endpoint was local control (LC), while the secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. The survival analysis was performed using Kaplan–Meier estimates in R v4.2.3. Results: In total, 48 patients receiving 135 SABR courses were included. The median age was 15.6 years (interquartile range, IQR 14–23 y) and the median follow-up was 18.1 months (IQR: 7.7–29.1). The median SABR dose was 30 Gy (IQR 25–35 Gy). The most common primary histologies were Ewing sarcoma (25%), rhabdomyosarcoma (17%), osteosarcoma (13%), and central nervous system (CNS) gliomas (13%). Furthermore, 57% of patients had oligometastatic disease (≤5 lesions) at the time of SABR. The one-year LC, PFS, and OS rates were 94%, 22%, and 70%, respectively. No grade 4 or higher toxicities were observed, while the rates of any grade 1, 2, and 3 toxicities were 11.8%, 3.7%, and 4.4%, respectively. Patients with oligometastatic disease, lung, or brain metastases and those who underwent surgery for a metastatic site had a significantly longer PFS. LC at 1-year was significantly higher for patients with a sarcoma histology (95.7% vs. 86.5%, p = 0.01) and for those who received a biological equivalent dose (BED10) > 48 Gy (100% vs. 91.2%, p = 0.001). Conclusions: SABR is well tolerated in pediatric patients with 1-year local failure and OS rates of <10% and 70%, respectively. Future studies evaluating SABR in combination with systemic therapy are needed to address progression outside of the irradiated field.